FindTrial
Sign In

Tokushima Anti-Oxidation Clinical Trial In hypertensives, Cilnidipine versus Amlodipine

Tokushima Anti-Oxidation Clinical Trial In hypertensives, Cilnidipine versus Amlodipine - TACTICAL

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001719
Enrollment
50
Registered
2009-02-23
Start date
2009-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

clinidipine (initial dose is 10mg/day, but 10-20mg is available depending on the blood pressure level) amlodipine (initial dose is 5mg/day, but 5-10mg is available depending on the blood pressure leve

Sponsors

Cardiovascular Medicine, The University of Tokushima Institute of Health Biosciences, Graduate School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Out patients 2.Patients who received an Antihypertensive treatment with RAS inhibitors. 3.Blood pressure (BP):systolic BP (SBP) 140mmHg and above or diastolic BP (DBP) 90mmHg and above.

Exclusion criteria

Exclusion criteria: 1.Malignant hypertension 2.Pregnant women,or Women suspected of being pregnant. 3.Severe liver disorder. 4.Patients who are inadequate to enter this study due to the other reasons by physician's judgments.

Design outcomes

Primary

MeasureTime frame
1.Clinic blood pressure,heart rate. 2.Home blood pressure,heart rate. 3.urinary 8-OHdG. 4.hs-CRP 5.urinary albumin-creatinine ratio. 6.urinary L-FABP. 7.LDL-C,TG,HDL-C,BUN,Cr,*HbA1c*fasting blood glucose(*Patients with diabetes)—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026